Dermatitis por contacto fotoalérgica a protectores solares con oxibenzona en La Plata, Argentina

Abstract

PACD to sunscreens containing oxybenzone is common and is probably underdiagnosed due to a lack of confirmation by photopatch tests or other diagnostic tools. Sensitization rates vary according to region and are influenced by sunscreen ingredients and variations in the use of sunscreen products, cosmetics, and topical drugs.

Standard photopatch test battery? Proposal based on current epidemiology and experience in our Skin Allergy Unit

“…This is how it is currently done in the European PPT battery, which includes solar filters (separately tested) and NSAIDs (Chemotechnique). Neither in the European Photopatch Baseline Series (EP‐1000) nor in the Extended one (EPE‐1000) are any fragrances included 1 . In our country, photoallergen batteries from MartiTor (Barcelona, Spain) do not include any fragrances either.…”

“…Neither in the European Photopatch Baseline Series (EP-1000) nor in the Extended one (EPE-1000) are any fragrances included. 1 In our country, photoallergen batteries from MartiTor (Barcelona, Spain) do not include any fragrances either. It is true that PPT significantly varies depending on the country, and only few countries include fragrances in PPT batteries.…”

“…Due to the necessary involvement of sunlight in provoking the skin lesions, they do not typically appear in areas that are anatomically protected from the sun, for example, upper eyelids and retroauricular folds. Involvement of the rest of the face and neck should raise suspicion on PACD 1 …”

“…Due to the necessary involvement of sunlight in provoking the skin lesions, they do not typically appear in areas that are anatomically protected from the sun, for example, upper eyelids and retroauricular folds.Involvement of the rest of the face and neck should raise suspicion on PACD. 1 Diagnosis is confirmed by photopatch testing (PPT), which consists of applying allergens to be studied in duplicate and exposing only half of them to broad-spectrum UVA radiation (320-400 nm) at a dose of 5 J/cm 2 after the first 24-48 hours [day (D)1 or D2] of occlusion (eg, coinciding with the first reading). Final reading usually takes place on D4 (96 hours).…”